Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Stockwatch: Alnylam Helps Nucleic Acid Drugs Degrade

Executive Summary

Clinical trial failures and holds for drugs derived from nucleic acids from Alnylam and Ionis join those of Dicerna and Genta as the hit rate for these drugs continues to degrade. The real question is whether the failures have been due to a lack of efficacy or safety.

Advertisement

Related Content

Stockwatch: Bluebird, Arrowhead And Short Memories
Alnylam Ends Revusiran In Phase III, But Was Failure Due To Safety Or Efficacy?
Ionis Antisense Platform Safety Questioned After Thrombocytopenia Seen In Studies
The end really is nigh for Genasense in melanoma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel